M B Gea Kiewiet1, Danijela Apostolovic1, Maria Starkhammar2, Jeanette Grundström1, Carl Hamsten1, Marianne van Hage3. 1. Department of Medicine Solna, Division of Immunology and Allergy, Karolinska Institutet and University Hospital, Stockholm, Sweden. 2. Department of Internal Medicine, Södersjukhuset, Stockholm, Sweden. 3. Department of Medicine Solna, Division of Immunology and Allergy, Karolinska Institutet and University Hospital, Stockholm, Sweden. Electronic address: marianne.van.hage@ki.se.
Abstract
BACKGROUND: The galactose-α1,3-galactose (α-Gal) syndrome (AGS) is a novel form of food allergy. Patients experience delayed severe allergic reactions after mammalian meat consumption due to IgE antibodies directed against the carbohydrate α-Gal present in mammalian meat. The onset of the disease is associated with tick bites. OBJECTIVE: To characterize a cohort of patients with AGS from Sweden on a clinical and serological level, and identify risk factors for disease severity. METHODS: A total of 128 patients with symptoms after mammalian meat intake and IgE to α-Gal were included. Medical examination and diagnosis were made by an allergologist and questionnaires were filled in regarding onset of symptoms, tick exposure, and airborne allergies. Serum IgE reactivity against multiple food and airborne allergens, as well as protein extract from the tick Ixodes ricinus, was measured using ImmunoCAP. RESULTS: The majority of patients were middle aged, with equal gender distribution. Nearly all reported symptoms more than 2 hours after meat consumption. Urticaria (90%) and gastrointestinal symptoms (74%) were most common. Almost half of the patients suffered from anaphylaxis, and α-Gal IgE levels were significantly higher among these patients compared with those without anaphylaxis. Nearly all patients had been tick bitten and 75% had IgE against I. ricinus. More than half of the patients with AGS were atopic, and atopy increased the risk of anaphylaxis with pulmonary manifestations. Only 2 patients belonged to blood group B/AB. CONCLUSION: AGS is an upcoming food allergy where patients report severe symptoms and tick bites. Atopy was found to affect the manifestation of the disease in Swedish patients.
BACKGROUND: The galactose-α1,3-galactose (α-Gal) syndrome (AGS) is a novel form of food allergy. Patients experience delayed severe allergic reactions after mammalian meat consumption due to IgE antibodies directed against the carbohydrate α-Gal present in mammalian meat. The onset of the disease is associated with tick bites. OBJECTIVE: To characterize a cohort of patients with AGS from Sweden on a clinical and serological level, and identify risk factors for disease severity. METHODS: A total of 128 patients with symptoms after mammalian meat intake and IgE to α-Gal were included. Medical examination and diagnosis were made by an allergologist and questionnaires were filled in regarding onset of symptoms, tick exposure, and airborne allergies. Serum IgE reactivity against multiple food and airborne allergens, as well as protein extract from the tick Ixodes ricinus, was measured using ImmunoCAP. RESULTS: The majority of patients were middle aged, with equal gender distribution. Nearly all reported symptoms more than 2 hours after meat consumption. Urticaria (90%) and gastrointestinal symptoms (74%) were most common. Almost half of the patients suffered from anaphylaxis, and α-Gal IgE levels were significantly higher among these patients compared with those without anaphylaxis. Nearly all patients had been tick bitten and 75% had IgE against I. ricinus. More than half of the patients with AGS were atopic, and atopy increased the risk of anaphylaxis with pulmonary manifestations. Only 2 patients belonged to blood group B/AB. CONCLUSION:AGS is an upcoming food allergy where patients report severe symptoms and tick bites. Atopy was found to affect the manifestation of the disease in Swedish patients.
Authors: Danijela Apostolovic; Jeanette Grundström; Marija Perusko; M B Gea Kiewiet; Carl Hamsten; Maria Starkhammar; Marianne van Hage Journal: Clin Transl Allergy Date: 2021-12-15 Impact factor: 5.871
Authors: Mensiena B G Kiewiet; Marija Perusko; Jeanette Grundström; Carl Hamsten; Maria Starkhammar; Danijela Apostolovic; Marianne van Hage Journal: Clin Transl Allergy Date: 2022-01-17 Impact factor: 5.871
Authors: Patricia Román-Carrasco; Wolfgang Hemmer; Alejandro Cabezas-Cruz; Adnan Hodžić; José de la Fuente; Ines Swoboda Journal: Front Allergy Date: 2021-12-16
Authors: Sara Olivera-Ardid; Daniel Bello-Gil; Alexander Tuzikov; Ricardo N Araujo; Yara Ferrero-Alves; Blanca Esther García Figueroa; Moisés Labrador-Horrillo; Ana L García-Pérez; Nicolai Bovin; Rafael Mañez Journal: Front Immunol Date: 2022-03-31 Impact factor: 7.561
Authors: Ksenja Riabova; Antonina V Karsonova; Marianne van Hage; Ulrika Käck; Jon R Konradsen; Hans Grönlund; Daria Fomina; Evgeny Beltyukov; Polina A Glazkova; Dmitry Yu Semenov; Rudolf Valenta; Alexander Karaulov; Mirela Curin Journal: Int J Mol Sci Date: 2022-06-23 Impact factor: 6.208
Authors: Paul J Turner; Stefania Arasi; Barbara Ballmer-Weber; Alessia Baseggio Conrado; Antoine Deschildre; Jennifer Gerdts; Susanne Halken; Antonella Muraro; Nandinee Patel; Ronald Van Ree; Debra de Silva; Margitta Worm; Torsten Zuberbier; Graham Roberts Journal: Allergy Date: 2022-04-28 Impact factor: 14.710